Telix Pharmaceuticals Limited Sponsored ADR TLX 深 滬
交易中 10-07 11:17:23 美东时间
11.045
+0.265
+2.46%
華盛通- 最 高11.08
- 今 開11.01
- 成交量 9.19万股
- 最 低 11.01
- 昨 收 10.78
- 總市值 37.42亿
- 52周最高 13.1098
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 6.28
- 委 比 -37.01%
- 總股本 3.39亿
- 歷史最高 30.36
- 量 比 1.50
- 振 幅 0.65%
- 歷史最低 6.28
- 每 手 1
- 風險率 1.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer). Pixclara addresses a significant unmet need helping physicians differentiate r...
10-06 18:31
Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse
Telix Pharmaceuticals Limited (NASDAQ:TLX) signed a strategic agreement on Sunday to merge with ITM Isotope Technologies Munich SE, a major global producer of radioisotopes. Following the announcement, TLX stock fell nearly 10%. This acquisition will make the combined organization a vertically integ...
09-21 22:52
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 1% on Monday. Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply in pre-market trading after the company released topline results from Phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly Cagrisema (Cagrilint...
09-21 20:04
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagnose brain cancer. Key Indications And Regulatory Milestone Pixclara serves as a r...
09-14 21:50
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA). Scholar Rock Holding shares jumpe...
09-14 17:50
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning1...
09-01 15:59
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
08-21 00:47
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON Study
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized,...
07-21 05:14
